Hypoparathyroidism: practice and theoretical backgrounds for 1 alpha(OH)D3 treatment. - Suppr | 超能文献

Hypoparathyroidism: practice and theoretical backgrounds for 1 alpha(OH)D3 treatment.

作者信息

Ogata E

机构信息

Fourth Department of Medicine, University of Tokyo School of Medicine, Japan.

出版信息

Bone Miner. 1990 Jun;9(3):229-32. doi: 10.1016/0169-6009(90)90040-m.

DOI:10.1016/0169-6009(90)90040-m

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Hypoparathyroidism: practice and theoretical backgrounds for 1 alpha(OH)D3 treatment.

Bone Miner. 1990 Jun;9(3):229-32. doi: 10.1016/0169-6009(90)90040-m.

2

Effect of intravenous 1-alpha-hydroxyvitamin D3 on secondary hyperparathyroidism in chronic uremic patients on maintenance hemodialysis.静脉注射1-α-羟维生素D3对维持性血液透析慢性尿毒症患者继发性甲状旁腺功能亢进的影响。

Nephron. 1989;53(3):194-200. doi: 10.1159/000185744.

3

[Oral pulsatile therapy with active vitamin D3 metabolites--an efficient method of parathyroid hormone synthesis suppression in uremic patients with severe hyperparathyroidism. A pilot study].

Pol Arch Med Wewn. 1993 Feb;89(2):95-101.

4

Treatment of secondary hyperparathyroidism with intermittent oral high doses of 1-alpha-OHD3 plus pharmacological dose of 24,25(OH)2D3.间歇性口服大剂量1-α-羟化胆钙化醇加药理剂量的24,25-二羟胆钙化醇治疗继发性甲状旁腺功能亢进

Ren Fail. 1994 Nov;16(6):715-23. doi: 10.3109/08860229409044901.

5

A randomized trial of intermittent versus continuous oral alfacalcidol treatment of hyperparathyroidism in end-stage renal disease.终末期肾病患者甲状旁腺功能亢进症间歇性与连续性口服阿法骨化醇治疗的随机试验

Clin Nephrol. 2006 Jun;65(6):415-8. doi: 10.5414/cnp65415.

6

Absence of effect of 24,25-dihydroxyvitamin D3 in primary hyperparathyroidism.24,25 - 二羟基维生素D3对原发性甲状旁腺功能亢进症无效。

J Clin Endocrinol Metab. 1986 Jul;63(1):246-8. doi: 10.1210/jcem-63-1-246.

7

Hormonal control of skeletal and mineral homeostasis.骨骼与矿物质稳态的激素调控

Am J Med. 1974 Jun;56(6):751-8. doi: 10.1016/0002-9343(74)90802-x.

8

Treatment with active vitamin D (alphacalcidol) in patients with mild primary hyperparathyroidism.活性维生素D（阿法骨化醇）治疗轻度原发性甲状旁腺功能亢进患者。

Acta Endocrinol (Copenh). 1989 Feb;120(2):250-6. doi: 10.1530/acta.0.1200250.

9

1-alpha-Hydroxyvitamin D3 derivatives in the treatment of renal bone diseases: justification and optimal modalities of administration.1-α-羟基维生素D3衍生物在治疗肾性骨病中的应用：依据及最佳给药方式

Nephron. 1995;71(3):254-83. doi: 10.1159/000188732.

10

Prevention of hyperparathyroidism in patients on maintenance dialysis by intravenous 1-alpha-hydroxyvitamin D3 in association with Mg(OH)2 as sole phosphate binder. A randomized comparative study with the association CaCO3 +/- Mg(OH)2.静脉注射1-α-羟维生素D3联合氢氧化镁作为单一磷结合剂预防维持性透析患者的甲状旁腺功能亢进。与碳酸钙±氢氧化镁联合使用的随机对照研究。

Nephron. 1992;60(2):154-63. doi: 10.1159/000186732.

引用本文的文献

1

Improving the outcome of established therapies for osteoporosis by adding the active D-hormone analog alfacalcidol.通过添加活性维生素D激素类似物阿法骨化醇来改善已有的骨质疏松症治疗效果。

Rheumatol Int. 2007 Dec;28(2):103-11. doi: 10.1007/s00296-007-0422-6. Epub 2007 Aug 1.

2

Prevention and therapy of osteoporosis: the roles of plain vitamin D and alfacalcidol.骨质疏松症的预防与治疗：普通维生素D和阿法骨化醇的作用

Rheumatol Int. 2004 Jul;24(4):189-97. doi: 10.1007/s00296-004-0454-0. Epub 2004 Jun 30.